Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from SciSparc Ltd. ( (SPRC) ).
On September 21, 2025, SciSparc Ltd. announced changes in its management, appointing Mr. Amitay Weiss as President and Mr. Itschak Shrem as Chairman of the Board. On September 25, 2025, SciSparc revealed plans to launch a quantum computing-enabled 3D protein modeling initiative aimed at revolutionizing AI drug discovery. This initiative seeks to improve the accuracy of protein structure predictions and interactions, potentially leading to breakthroughs in drug discovery for neurological and rare diseases. The company plans to form a dedicated research team and collaborate with experts in quantum computing and structural biology.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, and autism spectrum disorder. SciSparc also has a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 2,573,212
Technical Sentiment Signal: Sell
Current Market Cap: $2.05M
Find detailed analytics on SPRC stock on TipRanks’ Stock Analysis page.